The broader pharmaceutical sector periodically encounters headwinds due to escalating research and development costs, stringent regulatory compliance audits by global health authorities, pricing pressures from generic competition, and supply chain disruptions affecting raw material availability. Furthermore, patent expirations on blockbuster drugs, shifting macroeconomic interest rate environments, and high capital expenditure demands for biotechnology advancements create complex operating dynamics across global healthcare markets.